use of an ectonucleotide pyrophosphatase phosphodiesterase (npp1); use of a pharmaceutical composition; and use of an isolated recombinant human snpp1, fragment or fusion protein thereof

摘要

The present invention provides a method of treatment for npp1 deficiency or npp1-associated disease, such as idiopathic infantile arterial calcification (iiac), elastic pseudoxanthoma, vascular calcification in chronic renal disease (vcckd), insulin resistance, hypophosphatemic rickets, ischemia. myocardial infarction, joint calcification, angioid striae, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble npp1 to produce a transient increase in serum pyrophosphate levels.